- Home
- ACRS vs ACIU Comparison
ACRS vs ACIU Comparison
Compare ACRS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ACIU
- Stock Information
- Founded
- ACRS 2012
- ACIU 2003
- Country
- ACRS United States
- ACIU Switzerland
- Employees
- ACRS N/A
- ACIU N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- ACIU Health Care
- Exchange
- ACRS Nasdaq
- ACIU Nasdaq
- Market Cap
- ACRS 165.7M
- ACIU 189.1M
- IPO Year
- ACRS 2015
- ACIU 2016
- Fundamental
- Price
- ACRS $1.53
- ACIU $2.12
- Analyst Decision
- ACRS Strong Buy
- ACIU Strong Buy
- Analyst Count
- ACRS 9
- ACIU 1
- Target Price
- ACRS $9.25
- ACIU $12.00
- AVG Volume (30 Days)
- ACRS 1.4M
- ACIU 152.7K
- Earning Date
- ACRS 08-11-2025
- ACIU 08-12-2025
- Dividend Yield
- ACRS N/A
- ACIU N/A
- EPS Growth
- ACRS N/A
- ACIU N/A
- EPS
- ACRS N/A
- ACIU N/A
- Revenue
- ACRS $17,777,000.00
- ACIU $32,014,254.00
- Revenue This Year
- ACRS N/A
- ACIU N/A
- Revenue Next Year
- ACRS $8.11
- ACIU $533.21
- P/E Ratio
- ACRS N/A
- ACIU N/A
- Revenue Growth
- ACRS N/A
- ACIU 91.20
- 52 Week Low
- ACRS $1.05
- ACIU $1.43
- 52 Week High
- ACRS $5.17
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- ACIU 48.49
- Support Level
- ACRS $1.46
- ACIU $2.02
- Resistance Level
- ACRS $1.86
- ACIU $2.52
- Average True Range (ATR)
- ACRS 0.12
- ACIU 0.15
- MACD
- ACRS -0.02
- ACIU -0.02
- Stochastic Oscillator
- ACRS 17.54
- ACIU 23.08
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.